Ciprofloxacin/fluocinolone acetonide - SALVAT
Alternative Names: Cetraxal Comp; Cetraxal Plus; DF277/DF289; DF289/DF277; Duoxal; Fluocinolone acetonide/ciprofloxacin; Infalin Duo; Otixal; Otixal®; Otospon; Otovel; OTOVEL; Ultramicina PlusLatest Information Update: 24 Sep 2021
At a glance
- Originator SALVAT
- Developer Arbor Pharmaceuticals; Medexus Pharmaceuticals; SALVAT
- Class Anti-inflammatories; Antibacterials; Eye disorder therapies; Fluorinated steroids; Fluoroquinolones; Pregnadienes; Small molecules
- Mechanism of Action Arachidonic acid inhibitors; DNA topoisomerase IV inhibitors; Glucocorticoid receptor agonists; Phospholipase A2 inhibitors; Type II bacterial DNA topoisomerase inhibitors; Type II DNA topoisomerase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Marketed Otitis externa; Otitis media
Most Recent Events
- 24 Sep 2021 No development reported - Preregistration for Otitis externa in Canada (Otic)
- 19 Nov 2020 Lee's Pharmaceutical plans a phase III trial for Otitis externa (In children, In adolescent, In adult, In the elderly) in China, in November 2020 , (NCT04636957)
- 13 Dec 2018 Pediapharm is now called Medexus Pharmaceuticals